个人简介
苏州大学药学院教授，国家海外高层次人才计划青年项目获得者，江苏省双创人才，姑苏创新领军人才。 郑教授分别从美国约翰∙霍普金斯大学和美国麻省理工学院获得学士和博士学位，在新加坡科技研究局（A*STAR）从事研创工作后加盟苏州大学药学院。郑博士多年来在免疫学、生物科技和材料工程等的交叉领域研发了新型CAR-T细胞疗法、疫苗和其智能武装体系，高效治疗癌症和自身免疫性疾病。 以通讯或第一作者在Nature Biotechnology、Cell Reports Medicine (2x)、Advanced Materials (2x)、Nature Communications、ACS Nano、Journal of Controlled Release (2x) 等国际期刊发表成果，引用4100余次。主持国家自然科学基金、国家生物药技术创新中心细胞疗法“揭榜挂帅”技术攻关项目等国家和省市级项目。已获中、美等国授权专利8项，其中转让生物医药公司3项，基于相关技术的公司产品在美国开展临床试验。
教育经历
-
学士, 2006.09- 2009.05, 美国约翰霍普金斯大学, 学士
-
博士, 2010.09- 2015.11, 生物工程, 美国麻省理工学院, 博士
工作经历
-
2015- 2017, 新加坡科技研究局 (A*STAR), 博士后
-
2017- 2019, 新加坡科技研究局 (A*STAR), 科研员 (Research Scientist)
-
2019- 至今, 苏州大学药学院, 教授
社会职务
中国颗粒学会药物制剂与粒子设计专业委员会委员 中国抗癌协会纳米肿瘤学专业委员会委员 江苏省药理学会青委会副主委 期刊Fundamental Research等青年编委 Adv Mater、Cell Host & Microbe、Signal Transduction Targeted Ther、Adv Sci、J Exp Clin Canc Res等二十余本期刊审稿人
研究领域
结合免疫学、生物科技和材料工程，围绕癌症和自身免疫性疾病，研发新型CAR-T细胞疗法、癌症疫苗和相关智能药物递送体系。
社会职务
中国颗粒学会药物制剂与粒子设计专业委员会委员 中国抗癌协会纳米肿瘤学专业委员会委员 江苏省药理学会青委会副主委 期刊Fundamental Research等青年编委 Adv Mater、Cell Host & Microbe、Signal Transduction Targeted Ther、Adv Sci、J Exp Clin Canc Res等二十余本期刊审稿人
论文
-
1、 Lipid-engineered antibody-based therapeutics target inflamed joints and lymph nodes to enhance rheumatoid arthritis treatment, Cell Reports Medicine, 2026, Lei Zhao, Shan An, Mengqian Gao, Cui Shen, Meng Li, Yangjing Li, Ning Liu, Jin Chen, Wenjun Wan, Lichen Yin#, Yiran Zheng#, https://doi.org/10.1016/j.xcrm.2026.103094
-
2、DC-CD4 bispecific tolerogenic nanovesicles induce antigen-specific regulatory T cells and ameliorate collagen-induced arthritis inmice, Nature Communications, 2026, Lei Zhao, Zhongqiang Gao, Ze Yuan, Xiaodie Yang, Duxin Li, Qian Ren, Yunli Yu#, Jie Pan#, Yiran Zheng#, Xinyun Zhang#,17:4170
-
3、Cell Surface-tethered Nucleic Acid Therapeutics Program Robust and Tumor-responsive Enhancement of Adoptive Cell Therapy, Advanced Materials, 2025, Mengqian Gao, Ying Liu, Lei Zhao, Jin Chen, Wenjun Wan, Ze Yuan, Lingyu Li, Yulun Huang, Yajun Wang#, Yiran Zheng#, 37, 2419969
-
4、In situ therapeutic vaccines for leukemia by chemo-nanoadjuvant therapy, Journal of Controlled Release, 2025, Peng Zhang, Guanhong Cui, Tanzhen Wang, Xiaofei Zhao, Xinyue Wang, Ruonan Ye, Tianhui Liu#, Yiran Zheng#, Zhiyuan Zhong#, 383, 113851
-
5、Systemic multifunctional nanovaccines for potent personalized immunotherapy of acute myeloid leukemia, Advanced Materials, 2024, Peng Zhang, Tianzhen Wang, Guihong Cui,Ruonan Ye,Wenjun Wan, Tianhui Liu#, Yiran Zheng#, Zhiyuan Zhong#,36, 2407189
-
6、Chemokine-based injectable navigation system for enhancing CAR-T cell therapy against solid tumors, Advanced Functional Materials, 2024, Wenjun Wan, Wenqing Han, Jin Chen, Yangjing Li, Yiran Zheng#, 34, 2401161
-
7、Paravertebrally‐injected multifunctional hydrogel for sustained anti‐inflammation and pain relief in lumbar disc herniation, Advanced Healthcare Materials, 2024, Wenhao Deng, Jin Chen, Xinli Wang, Qianliang Wang, Lei Zhao, Jun Yan#, Yiran Zheng#, 13, 2401227
-
8、Uplifting anti-tumor immunotherapy with lymph node-targeted and ratio-controlled co-delivery of tumor cell lysate and adjuvant, Advanced Healthcare Materials, 2024, Guihong Cui, Yinping Sun, Liping Qu, Yiran Zheng#, Zhiyuan Zhong#, 13, 2303690
-
9、Roadmap to next-generation cancer vaccines, Journal of Controlled Release, 2022, Yiran Zheng#, Zhiyuan Zhong#, 347, 308-313
-
10、Enhancing adoptive T cell therapy for solid tumor with cell-surface anchored immune checkpoint Inhibitor nanogels, Nanomedicine:NBM, 2022, Xingye Chen, Mengqian Gao, Shan An, Lei Zhao, Wenqing Han, Wenjun Wan, Jin Chen, Siqi Ma, Wenhua Cai, Yanni Cao, Dawei Ding, Yi Yan Yang, Lifang Cheng#, Yiran Zheng#, 45,102591
-
11、Immune Checkpoint Inhibitor‐Based Strategies for Synergistic Cancer Therapy, Advanced Healthcare Materials, 2021, M. He, T. Yang, Y. Wang, M. Wang, X. Chen, Dawei Ding#, Yiran Zheng#, Huabing Chen#, 10(9): 2002104
-
12、Cationic polymer synergizing with chemotherapeutics and re-purposing antibiotics against cancer cells, Biomaterials Science, 2021, Yiran Zheng#, J. Kng, C. Yang, J. L. Hedrick,, Yi Yan Yang#, 9, 2174-2182
-
13、Enhancing T-cell therapy through TCR signaling-responsive nanoparticle drug delivery, Nature Biotechnology, 2018, Li Tang, Yiran Zheng (co-first author), M. Melo, L. Mabardi, A. P. Castano, Y.Q. Xie, N. Li, S. B. Kudchodkar, H. C. Wong, E. K. Jeng, M. V. Maus, Darrell Irvine#, 36 (8), 707 (2018)
-
14、Enhancing adoptive cell therapy of cancer through targeted delivery of small-molecule immunomodulators to internalizing or non-internalizing receptors, ACS Nano, 2017, Yiran Zheng, Li Tang, L. Mabardi, S. Kumari, Darrell Irvine#, 11(3):3089-3100
-
15、In vivo Targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes, Journal of Controlled Release, 2013, Yiran Zheng, M. T. Stephan, S. A. Gai, W. Abraham, A. Shearer, Darrell J. Irvine#, 172(2):426-35
-
16、Structure-based programming of lymph-node targeting in molecular vaccines, Nature, 2014, H. Liu, K. Moynihan, Y. Zheng, G. Szeto, A. Li, B. Huang, D. Egeren, C. Park, Darrell Irvine#, 507(7493): 519–522
招生信息
欢迎博士后和研究生加入团队：针对实体肿瘤和自身免疫性疾病，共同研发新型免疫细胞制备及改造技术，开发针对免疫细胞的智能药物递送系统。 拟招人员专业背景：免疫学、细胞生物学、药剂学或生物材料。
|
